Titre
Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Szucs, T. D.
Auteure/Auteur
Burnier, M.
Auteure/Auteur
Erne, P.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0920-3206
Statut éditorial
Publié
Date de publication
2004-09
Volume
18
Numéro
5
Première page
391
Dernière page/numéro d’article
7
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Sep
Research Support, Non-U.S. Gov't --- Old month value: Sep
Résumé
AIMS: To determine the economic benefit of losartan versus atenolol in patients with essential hypertension from the perspective of the Swiss healthcare system. METHODS AND RESULTS: The cost-effectiveness of losartan versus atenolol in the treatment of hypertension was analyzed by applying the results of the LIFE study to the Swiss healthcare system using a decision analysis framework.The cost-effectiveness shows the losartan cohort to provide an additional life expectancy of 0.05 years per patient compared to the atenolol cohort, over a mean follow-up period of 4.8 years. Losartan therapy in hypertensive patients produced net cost savings of CHF 24 per patient and per 4.8 years compared to atenolol from the perspective of the Swiss health care system. This result was robust after varying costs of medication, stroke, myocardial infarction and life expectancy. CONCLUSION: The use of a losartan-based regimen in hypertensive patients with left ventricular hypertrophy in Switzerland is net cost-saving compared with a atenolol-based regimen.
Sujets
PID Serval
serval:BIB_F4653BF5FD25
PMID
Date de création
2008-01-25T11:56:25.087Z
Date de création dans IRIS
2025-05-21T06:25:34Z